This therapy is a novel approach based in the lyse of tumor cells by a vaccina virus that promotes the release of tumor antigens that will trigger an anti-tumoral immune response, which could be resistant to exhaustion by blocking the PD-1/PD-L1 pathway [140]. Here, PDCD1 is linked to neoplasm.